Target intelligence / Profile preview

Transcobalamin receptor (CD320)

Target
CD320
Molecular classification
Receptor, Low-density lipoprotein receptor family
01

Overview

The transcobalamin receptor, also known as CD320, is a cell-surface receptor belonging to the low-density lipoprotein receptor family that mediates the cellular uptake of transcobalamin-bound vitamin B12 (cobalamin) via receptor-mediated endocytosis. It is expressed ubiquitously but is highly upregulated in actively proliferating cells, including various cancer cells, to support the high demand for vitamin B12 required for DNA synthesis and cell division. In addition to its role in nutrient uptake, CD320 is expressed on follicular dendritic cells and acts as a costimulator to promote germinal center B-cell differentiation and proliferation.

In oncology, CD320 is overexpressed in multiple cancers (such as multiple myeloma) and is being investigated as a target for antibody-drug conjugates, CAR-T cell therapies, and vitamin B12-conjugated therapeutics. Conversely, autoimmune B12 central deficiency is caused by pathogenic anti-CD320 autoantibodies that block the receptor at the blood-brain barrier, leading to severe neurological deficits despite normal systemic B12 levels. Therapeutic strategies targeting CD320 include experimental saporin-conjugated antibodies for cancer and novel lysosome-targeting chimeras designed to selectively degrade pathogenic anti-CD320 autoantibodies in autoimmune neurological conditions.

Other names
CD320 antigenCD320 moleculeTCblR8D6 antigenFDC-signaling molecule 8D6FDC-SM-8D6Transcobalamin II receptor
02

Mechanism of action

Receptor-mediated endocytosis of transcobalamin-bound cobalamin (vitamin B12); targeted drug delivery via conjugation to vitamin B12 or anti-CD320 antibodies; targeted degradation of pathogenic autoantibodies using lysosome-targeting chimeras (LYTACs).

03

Biological functions

Cobalamin uptakeB cell differentiationB cell proliferationEndocytosisCellular transport
04

Disease associations

CancerAutoimmune diseaseMultiple myelomaVitamin B12 deficiencyAutoimmune B12 central deficiencyNeurological disease
05

Safety considerations

Systemic vitamin B12 deficiencyNeurological impairment (demyelination, ataxia, cognitive decline) due to central B12 deficiencyPotential off-target effects on normal proliferating tissuesAutoimmune B12 central deficiency (ABCD) caused by anti-CD320 autoantibodies
06

Interacting drugs

99mTc-PAMA-cobalamin (experimental)

2 more in the full profile.

07

Biomarkers

CD320 expression levelAnti-CD320 autoantibodiesCerebrospinal fluid (CSF) vitamin B12 levelsMethylmalonic acid (MMA) levelsHomocysteine levels

Beyond the preview

Go deeper on Transcobalamin receptor (CD320).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Transcobalamin receptor (CD320).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call